喜欢 0
派生 0

最后活跃于 1751930342

metadata

d13forme 修订了这个 Gist 1751930342. 转到此修订

没有任何变更

d13forme 修订了这个 Gist 1751929949. 转到此修订

3 files changed, 0 insertions, 0 deletions

amass_scan_tripleharm_by.txt 重命名为 amass_scan_triplepharm_by.txt

文件已重命名，但内容与之前没有差异

links_en_tripleharm_by_WACDX.txt 重命名为 links_en_triplepharm_by_WACDX.txt

文件已重命名，但内容与之前没有差异

links_tripleharm_by_WACDX.txt 重命名为 links_triplepharm_by_WACDX.txt

文件已重命名，但内容与之前没有差异

d13forme 修订了这个 Gist 1751925054. 转到此修订

1 file changed, 47 insertions

links_en_tripleharm_by_WACDX.txt(文件已创建)

@@ -0,0 +1,47 @@
1 + https://en.triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%91%D0%B5%D0%BB.pdf
2 + https://en.triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%95%D0%90%D0%AD%D0%A1.pdf
3 + https://en.triplepharm.by/assets/files/antibiotikorezistentnost_eng.pdf
4 + https://en.triplepharm.by/assets/files/instrukciya-new-rus/Dorenem-instr.PDF
5 + https://en.triplepharm.by/assets/files/instrukciya-new-rus/Dorenem-instr.PDF
6 + https://en.triplepharm.by/assets/files/instrukciya-new-rus/IMP-Kolistat-avg2016.PDF
7 + https://en.triplepharm.by/assets/files/instrukciya-new-rus/IMP-Kolistat-avg2016.PDF
8 + https://en.triplepharm.by/assets/files/instrukciya-new-rus/instrukciya-imicinem.PDF
9 + https://en.triplepharm.by/assets/files/instrukciya-new-rus/instrukciya-imicinem.PDF
10 + https://en.triplepharm.by/assets/files/instrukciya-new-rus/instrukciya-Tejkoplanin-2017.PDF
11 + https://en.triplepharm.by/assets/files/instrukciya-new-rus/instrukciya-Tejkoplanin-2017.PDF
12 + https://en.triplepharm.by/assets/files/instrukciya-new-rus/Instrukciya-Vankomicin.pdf
13 + https://en.triplepharm.by/assets/files/instrukciya-new-rus/Instrukciya-Vankomicin.pdf
14 + https://en.triplepharm.by/assets/files/instrukciya-new-rus/Meropenem-instr.PDF
15 + https://en.triplepharm.by/assets/files/instrukciya-new-rus/Meropenem-instr.PDF
16 + https://en.triplepharm.by/assets/files/kolistin-u-detej-s-MV_eng.pdf
17 + https://en.triplepharm.by/assets/files/new-instr/dorenem-500-mg-dlya-infuzij.pdf
18 + https://en.triplepharm.by/assets/files/new-instr/dorenem-500-mg-dlya-infuzij.pdf
19 + https://en.triplepharm.by/assets/files/new-instr/imicinem-tf-500mg-500-mg-dlya-infuzij.pdf
20 + https://en.triplepharm.by/assets/files/new-instr/imicinem-tf-500mg-500-mg-dlya-infuzij.pdf
21 + https://en.triplepharm.by/assets/files/new-instr/imp-fosfomicin-tf.pdf
22 + https://en.triplepharm.by/assets/files/new-instr/imp-fosfomicin-tf.pdf
23 + https://en.triplepharm.by/assets/files/new-instr/imp_fosfomicin-tf-ing.pdf
24 + https://en.triplepharm.by/assets/files/new-instr/imp_fosfomicin-tf-ing.pdf
25 + https://en.triplepharm.by/assets/files/new-instr/kolistat-1-mln-dlya-ingalyacij.pdf
26 + https://en.triplepharm.by/assets/files/new-instr/kolistat-1-mln-dlya-ingalyacij.pdf
27 + https://en.triplepharm.by/assets/files/new-instr/kolistat-1-mln-me-dlya-vv-vvedeniya.pdf
28 + https://en.triplepharm.by/assets/files/new-instr/kolistat-1-mln-me-dlya-vv-vvedeniya.pdf
29 + https://en.triplepharm.by/assets/files/new-instr/kolistat-2-mln-me-dlya-vv-vvedeniya-i-ingalyacij.pdf
30 + https://en.triplepharm.by/assets/files/new-instr/kolistat-2-mln-me-dlya-vv-vvedeniya-i-ingalyacij.pdf
31 + https://en.triplepharm.by/assets/files/new-instr/meropenem-500-mg-1000-mg-dlya-vv-vvedeniya.pdf
32 + https://en.triplepharm.by/assets/files/new-instr/meropenem-500-mg-1000-mg-dlya-vv-vvedeniya.pdf
33 + https://en.triplepharm.by/assets/files/new-instr/meropenem-500-mg-1000-mg-dlya-vv-vvedeniya.pdf
34 + https://en.triplepharm.by/assets/files/new-instr/tejkoplanin-200-400-dlya-vv-i-vm-vvedeniya.pdf
35 + https://en.triplepharm.by/assets/files/new-instr/tejkoplanin-200-400-dlya-vv-i-vm-vvedeniya.pdf
36 + https://en.triplepharm.by/assets/files/new-instr/vankomicin-500-1000-dlya-infuzij.pdf
37 + https://en.triplepharm.by/assets/files/new-instr/vankomicin-500-1000-dlya-infuzij.pdf
38 + https://en.triplepharm.by/assets/files/new/instrukciya-klaribakcin-en.pdf
39 + https://en.triplepharm.by/assets/files/new/instrukciya-klaribakcin-en.pdf
40 + https://en.triplepharm.by/assets/files/new/klaribakcin.pdf
41 + https://en.triplepharm.by/assets/files/new/klaribakcin.pdf
42 + https://en.triplepharm.by/assets/files/polimiksini_eng.pdf
43 + http://en.triplepharm.by:80/assets/files/Primenenie-Tejkoplanina-TF-u-detej_eng.pdf
44 + https://en.triplepharm.by/assets/files/Primenenie-Tejkoplanina-TF_eng(1).pdf
45 + https://en.triplepharm.by/politika-pers.pdf
46 + https://en.triplepharm.by/politika-pers.pdf
47 + https://en.triplepharm.by/politika-pers.pdf

d13forme 修订了这个 Gist 1751777670. 转到此修订

2 files changed, 331 insertions

amass_scan_tripleharm_by.txt(文件已创建)

@@ -0,0 +1,49 @@
1 + triplepharm.by (FQDN) --> mx_record --> mail.triplepharm.by (FQDN)
2 + mail.triplepharm.by (FQDN) --> a_record --> 93.84.97.177 (IPAddress)
3 + 93.84.0.0/15 (Netblock) --> contains --> 93.84.97.177 (IPAddress)
4 + 6697 (ASN) --> managed_by --> BELPAK-AS BELPAK, BY (RIROrganization)
5 + 6697 (ASN) --> announces --> 93.84.0.0/15 (Netblock)
6 + triplepharm.by (FQDN) --> ns_record --> ns2.hoster.by (FQDN)
7 + triplepharm.by (FQDN) --> ns_record --> ns1.hoster.by (FQDN)
8 + triplepharm.by (FQDN) --> a_record --> 93.125.99.66 (IPAddress)
9 + triplepharm.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:7::84:12e (IPAddress)
10 + autodiscover.triplepharm.by (FQDN) --> a_record --> 93.84.97.177 (IPAddress)
11 + www.en.triplepharm.by (FQDN) --> a_record --> 93.125.99.66 (IPAddress)
12 + www.en.triplepharm.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:7::84:12e (IPAddress)
13 + 2a0a:7d80::/47 (Netblock) --> contains --> 2a0a:7d80:1:7::84:12e (IPAddress)
14 + 93.125.99.0/24 (Netblock) --> contains --> 93.125.99.66 (IPAddress)
15 + 6697 (ASN) --> announces --> 2a0a:7d80::/47 (Netblock)
16 + 6697 (ASN) --> announces --> 93.125.99.0/24 (Netblock)
17 + ftp.triplepharm.by (FQDN) --> a_record --> 93.125.99.66 (IPAddress)
18 + ftp.triplepharm.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:7::84:12e (IPAddress)
19 + localhost.triplepharm.by (FQDN) --> a_record --> 127.0.0.1 (IPAddress)
20 + localhost.triplepharm.by (FQDN) --> aaaa_record --> ::1 (IPAddress)
21 + 127.0.0.0/8 (Netblock) --> contains --> 127.0.0.1 (IPAddress)
22 + ::/127 (Netblock) --> contains --> ::1 (IPAddress)
23 + 0 (ASN) --> managed_by --> Not routed (RIROrganization)
24 + 0 (ASN) --> managed_by --> Reserved Network Address Blocks (RIROrganization)
25 + 0 (ASN) --> announces --> 127.0.0.0/8 (Netblock)
26 + 0 (ASN) --> announces --> ::/127 (Netblock)
27 + en.triplepharm.by (FQDN) --> mx_record --> mailbe05.hoster.by (FQDN)
28 + ns1.hoster.by (FQDN) --> a_record --> 93.125.30.200 (IPAddress)
29 + ns1.hoster.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:1::6:0 (IPAddress)
30 + en.triplepharm.by (FQDN) --> a_record --> 93.125.99.66 (IPAddress)
31 + en.triplepharm.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:7::84:12e (IPAddress)
32 + 93.125.30.0/23 (Netblock) --> contains --> 93.125.30.200 (IPAddress)
33 + 2a0a:7d80::/47 (Netblock) --> contains --> 2a0a:7d80:1:1::6:0 (IPAddress)
34 + 6697 (ASN) --> announces --> 93.125.30.0/23 (Netblock)
35 + ns2.hoster.by (FQDN) --> a_record --> 185.179.82.104 (IPAddress)
36 + ns2.hoster.by (FQDN) --> aaaa_record --> 2a0a:7d80:3:1::8 (IPAddress)
37 + _autodiscover._tcp.triplepharm.by (FQDN) --> srv_record --> mail.triplepharm.by (FQDN)
38 + 185.179.82.0/23 (Netblock) --> contains --> 185.179.82.104 (IPAddress)
39 + 2a0a:7d80:3::/48 (Netblock) --> contains --> 2a0a:7d80:3:1::8 (IPAddress)
40 + 12406 (ASN) --> managed_by --> BN-AS Belarussian data communication service provider. (RIROrganization)
41 + 12406 (ASN) --> announces --> 185.179.82.0/23 (Netblock)
42 + 35594 (ASN) --> managed_by --> TUTBY-AS (RIROrganization)
43 + 35594 (ASN) --> announces --> 2a0a:7d80:3::/48 (Netblock)
44 + 177.97.84.93.in-addr.arpa (FQDN) --> ptr_record --> mail.triplepharm.by (FQDN)
45 + mailbe05.hoster.by (FQDN) --> a_record --> 93.125.31.215 (IPAddress)
46 + mailbe05.hoster.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:1:0:2:5:0 (IPAddress)
47 + 93.125.30.0/23 (Netblock) --> contains --> 93.125.31.215 (IPAddress)
48 + 2a0a:7d80::/47 (Netblock) --> contains --> 2a0a:7d80:1:1:0:2:5:0 (IPAddress)
49 + ipv6.triplepharm.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:7::84:12e (IPAddress)

links_tripleharm_by_WACDX.txt(文件已创建)

@@ -0,0 +1,282 @@
1 + https://triplepharm.by/%D0%9B%D0%B8%D1%86%D0%B5%D0%BD%D0%B7%D0%B8%D1%8F.pdf
2 + https://triplepharm.by/%D0%9B%D0%B8%D1%86%D0%B5%D0%BD%D0%B7%D0%B8%D1%8F.pdf
3 + https://triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%91%D0%B5%D0%BB.pdf
4 + https://triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%91%D0%B5%D0%BB.pdf
5 + https://triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%95%D0%90%D0%AD%D0%A1.pdf
6 + https://triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%95%D0%90%D0%AD%D0%A1.pdf
7 + https://triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%95%D0%90%D0%AD%D0%A1.pdf
8 + https://triplepharm.by/assets/files/0305instr/dorenem.pdf
9 + https://triplepharm.by/assets/files/0305instr/dorenem.pdf
10 + https://triplepharm.by/assets/files/0305instr/dorenem.pdf
11 + https://triplepharm.by/assets/files/0305instr/imicinem.pdf
12 + https://triplepharm.by/assets/files/0305instr/imicinem.pdf
13 + https://triplepharm.by/assets/files/0305instr/imicinem.pdf
14 + https://triplepharm.by/assets/files/0305instr/klaribakcin.pdf
15 + https://triplepharm.by/assets/files/0305instr/klaribakcin.pdf
16 + https://triplepharm.by/assets/files/0305instr/klaribakcin.pdf
17 + https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-dlya-ingalyacij.pdf
18 + https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-dlya-ingalyacij.pdf
19 + https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-dlya-ingalyacij.pdf
20 + https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-me-dlya-vv-vvedeniya.pdf
21 + https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-me-dlya-vv-vvedeniya.pdf
22 + https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-me-dlya-vv-vvedeniya.pdf
23 + https://triplepharm.by/assets/files/0305instr/kolistat-2-mln-me-dlya-vv-vvedeniya-i-ingalyacij.pdf
24 + https://triplepharm.by/assets/files/0305instr/kolistat-2-mln-me-dlya-vv-vvedeniya-i-ingalyacij.pdf
25 + https://triplepharm.by/assets/files/0305instr/kolistat-2-mln-me-dlya-vv-vvedeniya-i-ingalyacij.pdf
26 + https://triplepharm.by/assets/files/0305instr/kolistat-2-mln.pdf
27 + https://triplepharm.by/assets/files/0305instr/kolistat-2-mln.pdf
28 + https://triplepharm.by/assets/files/0305instr/kolistat-2-mln.pdf
29 + https://triplepharm.by/assets/files/0305instr/meropenem.pdf
30 + https://triplepharm.by/assets/files/0305instr/meropenem.pdf
31 + https://triplepharm.by/assets/files/0305instr/meropenem.pdf
32 + https://triplepharm.by/assets/files/0305instr/miomin-instrukciya.PDF
33 + https://triplepharm.by/assets/files/0305instr/miomin-instrukciya.PDF
34 + https://triplepharm.by/assets/files/0305instr/miomin-instrukciya.PDF
35 + https://triplepharm.by/assets/files/0305instr/miomin-instrukciya.PDF
36 + https://triplepharm.by/assets/files/0305instr/tejkoplanin.pdf
37 + https://triplepharm.by/assets/files/0305instr/tejkoplanin.pdf
38 + https://triplepharm.by/assets/files/0305instr/tejkoplanin.pdf
39 + https://triplepharm.by/assets/files/0305instr/vankomicin.pdf
40 + https://triplepharm.by/assets/files/0305instr/vankomicin.pdf
41 + https://triplepharm.by/assets/files/0305instr/vankomicin.pdf
42 + http://triplepharm.by:80/assets/files/1.pdf
43 + http://triplepharm.by:80/assets/files/1.pdf
44 + http://triplepharm.by:80/assets/files/1.pdf
45 + http://triplepharm.by:80/assets/files/1.pdf
46 + http://www.triplepharm.by:80/assets/files/1.pdf
47 + http://triplepharm.by/assets/files/1.pdf
48 + http://triplepharm.by/assets/files/1.pdf
49 + http://triplepharm.by/assets/files/1.pdf
50 + https://triplepharm.by/assets/files/1706/imp-fosfomicin-tf.pdf
51 + https://triplepharm.by/assets/files/1706/imp-fosfomicin-tf.pdf
52 + https://triplepharm.by/assets/files/1706/imp-fosfomicin-tf.pdf
53 + https://triplepharm.by/assets/files/1706/imp_fosfomicin-tf-ing.pdf
54 + https://triplepharm.by/assets/files/1706/imp_fosfomicin-tf-ing.pdf
55 + https://triplepharm.by/assets/files/1706/ohlp-kolistat-3-mln-i-4-5-mln.pdf
56 + https://triplepharm.by/assets/files/1706/ohlp-kolistat-3-mln-i-4-5-mln.pdf
57 + https://triplepharm.by/assets/files/1706/ohlp-kolistat-3-mln-i-4-5-mln.pdf
58 + http://triplepharm.by:80/assets/files/annot-bronhomoss-utverzh_eng.pdf
59 + http://triplepharm.by:80/assets/files/annot-fitokordium-utverzh_eng.pdf
60 + http://triplepharm.by:80/assets/files/annot-gastroforte-utverzh_eng.pdf
61 + http://triplepharm.by:80/assets/files/annot-sedakalm-utverzh_eng.pdf
62 + http://triplepharm.by:80/assets/files/annot-sinu-fito-utverzh_eng.pdf
63 + http://triplepharm.by:80/assets/files/annot-sinu-kapli-utverzh_eng.pdf
64 + http://triplepharm.by:80/assets/files/antibiotikorezistentnost.pdf
65 + http://triplepharm.by:80/assets/files/antibiotikorezistentnost.pdf
66 + http://triplepharm.by/assets/files/antibiotikorezistentnost.pdf
67 + http://triplepharm.by/assets/files/antibiotikorezistentnost.pdf
68 + https://triplepharm.by/assets/files/antibiotikorezistentnost.pdf
69 + http://www.triplepharm.by:80/assets/files/Brinamid_eng.pdf
70 + http://triplepharm.by:80/assets/files/bronhomoss-annot.pdf
71 + http://triplepharm.by:80/assets/files/fitokordium-annot.pdf
72 + http://triplepharm.by:80/assets/files/gastroforte-annot.pdf
73 + http://triplepharm.by:80/assets/files/gastroforte-annot.pdf
74 + http://triplepharm.by/assets/files/IMP-Kolistat-avg2016.PDF
75 + http://www.triplepharm.by/assets/files/insruktiya-new-rus/Dorenem-instr.PDF
76 + http://www.triplepharm.by/assets/files/insruktiya-new-rus/IMP-Klaribakcin.pdf
77 + http://www.triplepharm.by/assets/files/insruktiya-new-rus/IMP-Kolistat-avg2016.PDF
78 + http://www.triplepharm.by/assets/files/insruktiya-new-rus/instrukciya-cefepim.PDF
79 + http://www.triplepharm.by/assets/files/insruktiya-new-rus/instrukciya-cefosulbaktam.PDF
80 + http://www.triplepharm.by/assets/files/insruktiya-new-rus/instrukciya-imicinem.PDF
81 + http://triplepharm.by/assets/files/insruktiya-new-rus/Instrukciya-Ivonna-Forte.PDF
82 + http://www.triplepharm.by:80/assets/files/insruktiya-new-rus/Instrukciya-Ivonna-Forte.PDF
83 + http://triplepharm.by:80/assets/files/insruktiya-new-rus/Instrukciya-Ivonna-Forte.PDF
84 + http://triplepharm.by/assets/files/insruktiya-new-rus/Instrukciya-Ivonna.PDF
85 + http://triplepharm.by/assets/files/insruktiya-new-rus/Instrukciya-Paulina.PDF
86 + http://www.triplepharm.by:80/assets/files/insruktiya-new-rus/Instrukciya-Paulina.PDF
87 + http://triplepharm.by:80/assets/files/insruktiya-new-rus/Instrukciya-Paulina.PDF
88 + http://www.triplepharm.by/assets/files/insruktiya-new-rus/instrukciya-Tejkoplanin-2017.PDF
89 + http://www.triplepharm.by/assets/files/insruktiya-new-rus/instrukciya-triksocef(14.07.2017).pdf
90 + http://www.triplepharm.by/assets/files/insruktiya-new-rus/Instrukciya-Vankomicin.pdf
91 + https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-ingalyacionnyj.pdf
92 + https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-ingalyacionnyj.pdf
93 + https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-ingalyacionnyj.pdf
94 + https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-vnutrivennyj.pdf
95 + https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-vnutrivennyj.pdf
96 + https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-vnutrivennyj.pdf
97 + http://www.triplepharm.by/assets/files/insruktiya-new-rus/Meropenem-instr.PDF
98 + http://triplepharm.by/assets/files/instr-kolistat-eng(1).pdf
99 + http://triplepharm.by:80/assets/files/instr-kolistat-eng.pdf
100 + http://triplepharm.by:80/assets/files/Instr-Tejkoplanin-TF_eng.pdf
101 + http://triplepharm.by:80/assets/files/Instr-Tejkoplanin-TF_eng.pdf
102 + http://triplepharm.by/assets/files/Instruction_Benustin_eng.pdf
103 + http://www.triplepharm.by:80/assets/files/Instruction_Benustin_eng.pdf
104 + http://www.triplepharm.by:80/assets/files/Instruction_Benustin_eng.pdf
105 + http://triplepharm.by/assets/files/Instrukciya-Benustin.PDF
106 + http://www.triplepharm.by:80/assets/files/instrukciya-Brinamid.PDF
107 + http://triplepharm.by:80/assets/files/instrukciya-Brinamid.PDF
108 + http://triplepharm.by:80/assets/files/instrukciya-cefepim-2015.pdf
109 + http://triplepharm.by:80/assets/files/instrukciya-cefepim.PDF
110 + http://triplepharm.by:80/assets/files/instrukciya-cefosulbaktam.pdf
111 + http://triplepharm.by:80/assets/files/instrukciya-dorenem(1).pdf
112 + http://triplepharm.by:80/assets/files/instrukciya-dorenem_eng.pdf
113 + http://triplepharm.by:80/assets/files/instrukciya-imicinem.PDF
114 + http://triplepharm.by:80/assets/files/instrukciya-imipenem-2015.pdf
115 + http://triplepharm.by:80/assets/files/Instrukciya-Ivonna_eng(2).pdf
116 + http://www.triplepharm.by:80/assets/files/Instrukciya-Ivonna_eng(2).pdf
117 + http://triplepharm.by:80/assets/files/Instrukciya-Ivonna_eng(2).pdf
118 + http://www.triplepharm.by:80/assets/files/Instrukciya-Ivonna_eng(2).pdf
119 + http://triplepharm.by:80/assets/files/Instrukciya-Ivonna_eng(2).pdf
120 + http://triplepharm.by:80/assets/files/instrukciya-kapreocin(1).PDF
121 + https://triplepharm.by/assets/files/instrukciya-kapreocin(1).PDF
122 + https://triplepharm.by/assets/files/instrukciya-kapreocin(1).PDF
123 + https://triplepharm.by/assets/files/instrukciya-kapreocin(1).PDF
124 + http://triplepharm.by:80/assets/files/instrukciya-kapreocin-angl.pdf
125 + https://triplepharm.by/assets/files/instrukciya-kapreocin-angl.pdf
126 + http://triplepharm.by/assets/files/instrukciya-kapreocin-angl.pdf
127 + https://triplepharm.by/assets/files/instrukciya-kapreocin-angl.pdf
128 + https://triplepharm.by/assets/files/instrukciya-kapreocin-angl.pdf
129 + http://www.triplepharm.by/assets/files/Instrukciya-Klaribakcin-en.pdf
130 + https://triplepharm.by/assets/files/Instrukciya-Klaribakcin-en.pdf
131 + https://triplepharm.by/assets/files/Instrukciya-Klaribakcin-en.pdf
132 + https://triplepharm.by/assets/files/Instrukciya-Klaribakcin-en.pdf
133 + http://triplepharm.by:80/assets/files/instrukciya-kolistat(1).PDF
134 + http://triplepharm.by:80/assets/files/instrukciya-Meropenem(1).pdf
135 + http://triplepharm.by:80/assets/files/instrukciya-Triksocef_eng.pdf
136 + http://triplepharm.by:80/assets/files/instrukciya-vankomicin(1).pdf
137 + http://triplepharm.by:80/assets/files/instrukciya-vankomicin_eng.pdf
138 + http://triplepharm.by:80/assets/files/InstrukciyaCefosulb-na-utv-----(1).pdf
139 + http://triplepharm.by:80/assets/files/InstrukciyaMeropenem.pdf
140 + http://triplepharm.by:80/assets/files/InstrukciyaTejkoplanin.pdf
141 + http://triplepharm.by:80/assets/files/InstrukciyaTejkoplanin.pdf
142 + http://triplepharm.by:80/assets/files/InstrukciyaTriksocef.pdf
143 + http://triplepharm.by:80/assets/files/InstrukciyaTriksocef.pdf
144 + http://triplepharm.by:80/assets/files/lechenie-sinegnojnoj-infekcii.pdf
145 + https://triplepharm.by/assets/files/new-eng/dorenem-500-mg-dlya-infuzij.pdf
146 + https://triplepharm.by/assets/files/new-eng/dorenem-500-mg-dlya-infuzij.pdf
147 + https://triplepharm.by/assets/files/new-eng/dorenem-500-mg-dlya-infuzij.pdf
148 + https://triplepharm.by/assets/files/new-eng/imicinem-tf-500mg-500-mg-dlya-infuzij.pdf
149 + https://triplepharm.by/assets/files/new-eng/imicinem-tf-500mg-500-mg-dlya-infuzij.pdf
150 + https://triplepharm.by/assets/files/new-eng/imicinem-tf-500mg-500-mg-dlya-infuzij.pdf
151 + https://triplepharm.by/assets/files/new-eng/meropenem-500-mg-1000-mg-dlya-vv-vvedeniya.pdf
152 + https://triplepharm.by/assets/files/new-eng/meropenem-500-mg-1000-mg-dlya-vv-vvedeniya.pdf
153 + https://triplepharm.by/assets/files/new-eng/meropenem-500-mg-1000-mg-dlya-vv-vvedeniya.pdf
154 + https://triplepharm.by/assets/files/new-eng/tejkoplanin-200-400-dlya-vv-i-vm-vvedeniya.pdf
155 + https://triplepharm.by/assets/files/new-eng/tejkoplanin-200-400-dlya-vv-i-vm-vvedeniya.pdf
156 + https://triplepharm.by/assets/files/new-eng/tejkoplanin-200-400-dlya-vv-i-vm-vvedeniya.pdf
157 + https://triplepharm.by/assets/files/new-eng/vankomicin-500-1000-dlya-infuzij.pdf
158 + https://triplepharm.by/assets/files/new-eng/vankomicin-500-1000-dlya-infuzij.pdf
159 + https://triplepharm.by/assets/files/new-eng/vankomicin-500-1000-dlya-infuzij.pdf
160 + https://triplepharm.by/assets/files/PNPC-DOiGI(pilotnPrimTejkopl).pdf
161 + https://triplepharm.by/assets/files/PNPC-DOiGI(pilotnPrimTejkopl).pdf
162 + http://triplepharm.by/assets/files/Saj-InstrukciyaPaulina_eng.pdf
163 + http://triplepharm.by:80/assets/files/Saj-InstrukciyaPaulina_eng.pdf
164 + http://www.triplepharm.by:80/assets/files/Saj-InstrukciyaPaulina_eng.pdf
165 + http://triplepharm.by:80/assets/files/Saj-InstrukciyaPaulina_eng.pdf
166 + http://www.triplepharm.by:80/assets/files/Saj-InstrukciyaPaulina_eng.pdf
167 + http://triplepharm.by:80/assets/files/Saj-InstrukciyaPaulina_eng.pdf
168 + http://triplepharm.by:80/assets/files/Saj-paulina(inst)rus.pdf
169 + http://triplepharm.by:80/assets/files/Saj-paulina(inst)rus.pdf
170 + http://www.triplepharm.by:80/assets/files/Saj-paulina(inst)rus.pdf
171 + http://triplepharm.by:80/assets/files/Saj-paulina(inst)rus.pdf
172 + http://www.triplepharm.by:80/assets/files/SAJT-ivonna(instr)rus.pdf
173 + http://triplepharm.by:80/assets/files/SAJT-ivonna(instr)rus.pdf
174 + http://www.triplepharm.by:80/assets/files/SAJT-ivonna(instr)rus.pdf
175 + http://triplepharm.by:80/assets/files/SAJT-ivonna(instr)rus.pdf
176 + http://triplepharm.by:80/assets/files/sajt-ivonnaForte(inst)rus.pdf
177 + http://www.triplepharm.by:80/assets/files/sajt-ivonnaForte(inst)rus.pdf
178 + http://triplepharm.by:80/assets/files/sajt-ivonnaForte(inst)rus.pdf
179 + http://triplepharm.by:80/assets/files/SajtIvonnaForte(instr)angl.pdf
180 + http://www.triplepharm.by:80/assets/files/SajtIvonnaForte(instr)angl.pdf
181 + http://triplepharm.by:80/assets/files/SajtIvonnaForte(instr)angl.pdf
182 + http://www.triplepharm.by:80/assets/files/SajtIvonnaForte(instr)angl.pdf
183 + http://triplepharm.by:80/assets/files/SajtIvonnaForte(instr)angl.pdf
184 + http://triplepharm.by:80/assets/files/sedakalm-annot.pdf
185 + http://triplepharm.by:80/assets/files/sinu-fito-annot.pdf
186 + http://triplepharm.by:80/assets/files/sinu-kapli-annot.pdf
187 + http://www.triplepharm.by:80/assets/files/Slavena-forte-instrukciya.pdf
188 + http://triplepharm.by:80/assets/files/Slavena-forte-instrukciya.pdf
189 + http://www.triplepharm.by:80/assets/files/Slavena-instrukciya.pdf
190 + http://triplepharm.by:80/assets/files/Slavena-instrukciya.pdf
191 + http://www.triplepharm.by:80/assets/files/Slavena-instrukciya.pdf
192 + http://triplepharm.by:80/assets/files/Slavena-instrukciya.pdf
193 + https://triplepharm.by/assets/files/tejkoplanin--tf-3.pdf
194 + https://triplepharm.by/att1.pdf
195 + https://triplepharm.by/att1.pdf
196 + https://triplepharm.by/att1.pdf
197 + https://triplepharm.by/licenziya.pdf
198 + https://triplepharm.by/licenziya.pdf
199 + https://triplepharm.by/licenziya.pdf
200 + https://triplepharm.by/pdf/%D0%94%D0%BE%D0%B7%D0%B8%D1%80%D0%BE%D0%B2%D0%BE%D1%87%D0%BD%D0%B0%D1%8F%20%D0%BC%D0%B0%D1%88%D0%B8%D0%BD%D0%B0%20SP%20100.pdf
201 + https://triplepharm.by/pdf/%D0%94%D0%BE%D0%B7%D0%B8%D1%80%D0%BE%D0%B2%D0%BE%D1%87%D0%BD%D0%B0%D1%8F%20%D0%BC%D0%B0%D1%88%D0%B8%D0%BD%D0%B0%20SP%20100.pdf
202 + https://triplepharm.by/pdf/%D0%9F%D0%BE%D0%BB%D1%83%D0%B0%D0%B2%D1%82%D0%BE%D0%BC%D0%B0%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B0%D1%8F%20%D0%BE%D0%B1%D0%BA%D0%B0%D1%82%D0%BA%D0%B0.pdf
203 + https://triplepharm.by/pdf/%D0%A0%D0%BE%D1%82%D0%BE%D1%80%D0%BD%D1%8B%D0%B9%20%D1%81%D1%82%D0%BE%D0%BB.pdf
204 + https://triplepharm.by/pdf/%D0%A0%D0%BE%D1%82%D0%BE%D1%80%D0%BD%D1%8B%D0%B9%20%D1%81%D1%82%D0%BE%D0%BB.pdf
205 + https://triplepharm.by/pdf/3-samson.pdf
206 + https://triplepharm.by/pdf/4-tapalskij.pdf
207 + https://triplepharm.by/pdf/4-tapalskij.pdf
208 + https://triplepharm.by/politika-pers.pdf
209 + https://triplepharm.by/politika-pers.pdf
210 + https://triplepharm.by/politika-pers.pdf
211 + https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/certificatGMP-EAES.pdf
212 + https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/certificatGMP.pdf
213 + https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/dorenem.pdf
214 + https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/ertapenem.pdf
215 + https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/fosfomicin-2g.pdf
216 + https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/fosfomicin-5g.pdf
217 + https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/imicinem.pdf
218 + https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/klaribakcin.pdf
219 + https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/kolistat-1-mln.pdf
220 + https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/kolistat-2-mln.pdf
221 + https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/kolistat-3-mln-i-4-5-mln.pdf
222 + https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/licenziya.pdf
223 + https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/meropenem.pdf
224 + https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/partners.pdf
225 + https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/policy.pdf
226 + https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/tejkoplanin.pdf
227 + https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/vankomicin.pdf
228 + https://triplepharm.by/wp-content/uploads/1-doriprem.pdf
229 + https://triplepharm.by/wp-content/uploads/10-article.pdf
230 + https://triplepharm.by/wp-content/uploads/13-article.pdf
231 + https://triplepharm.by/wp-content/uploads/2-article.pdf
232 + https://triplepharm.by/wp-content/uploads/3-article.pdf
233 + https://triplepharm.by/wp-content/uploads/4-article.pdf
234 + https://triplepharm.by/wp-content/uploads/5-article.pdf
235 + https://triplepharm.by/wp-content/uploads/6-article.pdf
236 + https://triplepharm.by/wp-content/uploads/7-article.pdf
237 + https://triplepharm.by/wp-content/uploads/9-article.pdf
238 + https://triplepharm.by/wp-content/uploads/certificatgmp-eaes2025.pdf
239 + https://triplepharm.by/wp-content/uploads/certificatgmp2025.pdf
240 + https://triplepharm.by/wp-content/uploads/dorenem.pdf
241 + https://triplepharm.by/wp-content/uploads/dorenem_en.pdf
242 + https://triplepharm.by/wp-content/uploads/ertapenem.pdf
243 + https://triplepharm.by/wp-content/uploads/ertapenem_en.pdf
244 + https://triplepharm.by/wp-content/uploads/fosfomicin-2g.pdf
245 + https://triplepharm.by/wp-content/uploads/fosfomicin-5g.pdf
246 + https://triplepharm.by/wp-content/uploads/fosfomicin_en.pdf
247 + https://triplepharm.by/wp-content/uploads/imicinem.pdf
248 + https://triplepharm.by/wp-content/uploads/imicinem_en.pdf
249 + https://triplepharm.by/wp-content/uploads/klaribakcin.pdf
250 + https://triplepharm.by/wp-content/uploads/klaribakcin_en.pdf
251 + https://triplepharm.by/wp-content/uploads/kolistat-1-mln.pdf
252 + https://triplepharm.by/wp-content/uploads/kolistat-2-mln.pdf
253 + https://triplepharm.by/wp-content/uploads/kolistat-2-mln_en.pdf
254 + https://triplepharm.by/wp-content/uploads/kolistat-3-mln-i-4-5-mln.pdf
255 + https://triplepharm.by/wp-content/uploads/kolistat-3-mln-i-4-5-mln_en.pdf
256 + https://triplepharm.by/wp-content/uploads/licenziya.pdf
257 + https://triplepharm.by/wp-content/uploads/meropenem.pdf
258 + https://triplepharm.by/wp-content/uploads/meropenem_en.pdf
259 + https://triplepharm.by/wp-content/uploads/partners.pdf
260 + https://triplepharm.by/wp-content/uploads/policy.pdf
261 + https://triplepharm.by/wp-content/uploads/reprint_patogen-speczifichnaya-terapiya-1.pdf
262 + https://triplepharm.by/wp-content/uploads/tejkoplanin.pdf
263 + https://triplepharm.by/wp-content/uploads/tejkoplanin_en.pdf
264 + https://triplepharm.by/wp-content/uploads/vankomicin.pdf
265 + https://triplepharm.by/wp-content/uploads/vankomicin_en.pdf
266 + http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc
267 + http://triplepharm.by/assets/files/anketa_soiskatelya_tnk(2).doc
268 + http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc
269 + http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc
270 + http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc
271 + http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc
272 + http://www.triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc
273 + http://www.triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc
274 + http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
275 + http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
276 + http://www.triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
277 + http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
278 + http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
279 + http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
280 + http://www.triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
281 + http://www.triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
282 + http://triplepharm.by/123.rtf
上一页 下一页

由 Opengist 强力驱动 ⋅ Load: 89ms⋅

中文